Highlights From The Comments On Semaglutide

Companion to Semaglutidonomics (ACX-376, 72). A rich, practical companion aggregating commenter expertise on GLP-1 weight-loss drugs: burritosol's seven-point correction (supply shortages, Ozempic-for-weight-loss undercounting, list-vs-net pricing, the Cagrisema combo that stacks to ~30% loss); a compounding pharmacist's shortage-compounding legality + the 'reverse insurance' copay-card / PBM-rebate critique; grey-market Chinese-peptide sourcing; bariatric surgery now safer than gallbladder removal; the stay-on-forever question (2/3 weight regain after withdrawal) vs set-point-reset anecdotes; and vivid personal anecdotes (incl. Yudkowsky's non-response and the guess that >50% get nothing, and the socially-isolating loss-of-appetite testimony). Closes with a tedious-tangents index. Value is high but it is mostly curated tips + light Scott replies, with less original synthesis than the top companions.

Quality 69 · Strong. Solid-to-Strong, mid Highlights-companion band (~69). Genuinely useful and information-dense, but the thrust is aggregating others' practical knowledge with brief replies rather than Scott's own synthesis, so below the Ivermectin/San-Fransicko companions.

Claude’s paradigm shift 48 · Moderate. Moderate (48). Consolidates then-current knowledge (pricing mechanics, set-point, the combo pipeline) without an original frame.

Real-world impact 1 · Negligible. 1 — a companion commentary; negligible independent real-world effect.